摘要
目的探讨齐拉西酮治疗精神分裂症的疗效与安全性。方法采用开放性治疗与利培酮对照方法,将符合CC-MD-3诊断标准100例精神分裂症随机分为2组各50例,研究组给予齐拉西酮片120～160mg,对照组给予利培酮片5mg/d,疗程8周。采用PANSS量表、副反应量表(TESS)评定疗效和不良反应。结果显效率(痊愈+显进)为75.9%,对照组为75.8%,2组之间无显著差异(P>0.05)。研究组作用起效快,不良反应发生率低,与对照组比较差异显著。结论齐拉西酮抗精神病作用起效快,疗效与利培酮相当,不良反应轻,安全性高。
Objective To explore the efficacy and safety of Ziprasidone in the treatment of schizophrenia. Methods One hundred patients who met CCMD-3 formania were randomly assigned into two groups . The study group was treated with Ziprasidone 120-160mg every day and control group with Risperidone 5mg every day for eight weeks. The PANSS including recovery,obvious improve, improve, invalid, and treatment emergent side effect scale （TESS）were used to evaluate efficacy and adverse effects. Results The total effective rates for Ziprasidone and Risperidone were 75.9% and 75.8% . There were no signicant differences between the two groups（P〉0.05）. Ziprasidone showed more rapid effects significantly. Conclusion Ziprasidone is effective than Risperidone in the treatment of schizophrenia, and shows more rapid effects, fewer side effects and higher safety.
出处
《中国实用神经疾病杂志》
2009年第13期31-33,共3页
Chinese Journal of Practical Nervous Diseases
